Category: Press Releases
Kizoo Invests in Rejuvenation Startup MoglingBio
October 26, 2022
Having received new funding from Kizoo Technology Capital in its first seed round, MoglingBio intends to further its research into the rejuvenation of aging stem cells, finding ways to stave
Magnitude Reveals a New Target for Aging Therapeutics
September 27, 2022
At Longevity Summit Dublin, Ethan Perlstein and Magnitude Biosciences revealed that a small molecule, SMER28, improves longevity in C. elegans, a common model of aging. Background One of the greatest
SENS Research Foundation Announces Ending Aging Forum 2022
August 15, 2022
SENS Research Foundation has announced this year’s Ending Aging Forum, which will be held through a virtual conference platform with an immersive environment. Come spend a wonderful and thought provoking
Bioreactor-Grown Mitochondria for Potential Anti-Aging
July 19, 2022
Researchers from the University of Connecticut, Stanford University, Université Laval Quebec, and NSU Florida have helped test large-scale exogenous mitochondrial transplants in animal disease models and in-vitro human cells. The
Second Rejuveron Company Transitions into Clinical Stage
July 12, 2022
Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce that the first participant has been treated in Endogena Therapeutics’ phase
Molecule Raises $12.7 Million in Seed Funding for Biotech
June 30, 2022
Switzerland, Jun 30, 2022 – Molecule, a comprehensive funding and incubation ecosystem for early-stage biopharma research, announced this week they raised $12.7 million in seed funding. The round was led
NOVOS Reports Effectiveness Against DNA Damage
June 15, 2022
NEW YORK – June 15, 2022 – NOVOS, a company that develops science-based products to slow down aging, announced results of two studies demonstrating that the combination of ingredients in
Maximon Startup AVEA Closes 2.5M CHF Funding Round
June 1, 2022
The longevity company builder Maximon has concluded a financing round for AVEA at this year’s World Economic Forum. The press release is included here. ZUG, SWITZERLAND — AVEA, the longevity
First Cohort Dosed in Phase 1b Trial of BioAge’s BGE-105
April 19, 2022
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below
Kizoo Company Elastrin Closes $10M Funding Round
April 7, 2022
The well-known biotechnology holding company Kizoo has engaged in another funding round, this time for Elastrin Therapeutics, a company that focuses on returning stiff tissues to their natural state. The
Insilico Medicine Identifies New Aging Targets
March 30, 2022
Insilico Medicine, which uses AI for drug discovery, has identified potential dual-purpose therapeutic targets that are implicated in aging and age-associated diseases using artificial intelligence and a Hallmarks of Aging
Kizoo and Revel Announce $8.4 Million Seed Round
March 18, 2022
Revel Pharmaceuticals, a holding of Kizoo Technology Capital, has announced that it is seeking $8.4 million dollars in investment funding in order to develop its enzyme-based approach towards ending age-related
New Partnership Between Molecule, Apollo, and VitaDAO
February 21, 2022
Combining a Web3 IP market, venture capital, and a decentralized autonomous organization (DAO), three companies have banded together to create a new decentralized science ecosystem. The full press release is
Novartis Licenses mTOR Analogs to Cambrian Biopharma
February 17, 2022
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase
Altos Labs’ $3 Billion Launch to Reverse Cellular Aging
January 20, 2022
In September 2021, we reported that Altos Labs was about to launch an ambitious project to develop partial cellular reprogramming to the point where it could be safely used in
Kizoo Invests in Rejuvenation Startup MoglingBio
October 26, 2022
Having received new funding from Kizoo Technology Capital in its first seed round, MoglingBio intends to further its research into the rejuvenation of aging stem cells, finding ways to stave off stem cell exhaustion. Berlin/Ulm, Germany – October 26, 2022 – MoglingBio, a privately held biotech
Magnitude Reveals a New Target for Aging Therapeutics
September 27, 2022
At Longevity Summit Dublin, Ethan Perlstein and Magnitude Biosciences revealed that a small molecule, SMER28, improves longevity in C. elegans, a common model of aging. Background One of the greatest challenges for biomedical sciences is how to slow ageing. Ageing is the major risk factor for
SENS Research Foundation Announces Ending Aging Forum 2022
August 15, 2022
SENS Research Foundation has announced this year’s Ending Aging Forum, which will be held through a virtual conference platform with an immersive environment. Come spend a wonderful and thought provoking time with the team at SENS Research Foundation. This virtual event is your opportunity to hear
Bioreactor-Grown Mitochondria for Potential Anti-Aging
July 19, 2022
Researchers from the University of Connecticut, Stanford University, Université Laval Quebec, and NSU Florida have helped test large-scale exogenous mitochondrial transplants in animal disease models and in-vitro human cells. The results suggest broad efficacy for targeting the immune system, brain, retina, liver, skin, and systemic anti-aging.
Second Rejuveron Company Transitions into Clinical Stage
July 12, 2022
Rejuveron Life Sciences AG (‘Rejuveron’), a Zürich-based biotechnology company developing therapies to promote healthy aging, is pleased to announce that the first participant has been treated in Endogena Therapeutics’ phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP).
Molecule Raises $12.7 Million in Seed Funding for Biotech
June 30, 2022
Switzerland, Jun 30, 2022 – Molecule, a comprehensive funding and incubation ecosystem for early-stage biopharma research, announced this week they raised $12.7 million in seed funding. The round was led by Northpond Ventures with participation from Shine Capital, 1kx, Fifty Years, KdT Ventures, BACKED VC, Inflection
NOVOS Reports Effectiveness Against DNA Damage
June 15, 2022
NEW YORK – June 15, 2022 – NOVOS, a company that develops science-based products to slow down aging, announced results of two studies demonstrating that the combination of ingredients in its products, NOVOS Core and NOVOS Boost, protect against DNA damage and cellular aging (senescence). A
Maximon Startup AVEA Closes 2.5M CHF Funding Round
June 1, 2022
The longevity company builder Maximon has concluded a financing round for AVEA at this year’s World Economic Forum. The press release is included here. ZUG, SWITZERLAND — AVEA, the longevity supplement startup with the aim to improve healthspan, announces the closing of a 2.5 million CHF
First Cohort Dosed in Phase 1b Trial of BioAge’s BGE-105
April 19, 2022
BioAge, a biotechnology company that intends to target aging on the molecular level, has completed a Phase 1b clinical trial of BGE-105, a small molecule that influences muscular metabolism. Below is the company’s full press release. RICHMOND, Calif.–(BUSINESS WIRE)– BioAge Labs, Inc., a biotechnology company developing
Kizoo Company Elastrin Closes $10M Funding Round
April 7, 2022
The well-known biotechnology holding company Kizoo has engaged in another funding round, this time for Elastrin Therapeutics, a company that focuses on returning stiff tissues to their natural state. The full press release is included here. Greenville, SC, U.S, April 7, 2022 – Elastrin Therapeutics Inc.,
Insilico Medicine Identifies New Aging Targets
March 30, 2022
Insilico Medicine, which uses AI for drug discovery, has identified potential dual-purpose therapeutic targets that are implicated in aging and age-associated diseases using artificial intelligence and a Hallmarks of Aging framework. The full press release is included here. March 29, 2022, New York (11AM ET) —
Kizoo and Revel Announce $8.4 Million Seed Round
March 18, 2022
Revel Pharmaceuticals, a holding of Kizoo Technology Capital, has announced that it is seeking $8.4 million dollars in investment funding in order to develop its enzyme-based approach towards ending age-related diseases. The full press release is included below. Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed
New Partnership Between Molecule, Apollo, and VitaDAO
February 21, 2022
Combining a Web3 IP market, venture capital, and a decentralized autonomous organization (DAO), three companies have banded together to create a new decentralized science ecosystem. The full press release is included here. Feb. 21, 2022, Switzerland — Molecule, a biotech IP Web3 marketplace, announces a tripartite
Novartis Licenses mTOR Analogs to Cambrian Biopharma
February 17, 2022
Following the efforts of Adicet Bio, formerly resTORbio, to create therapies based on the mTOR pathway, Cambrian Biopharma is working with Novartis to use this pathway in order to increase healthspan and lifespan. The full press release is included here. NEW YORK, Feb. 16, 2022Â /PRNewswire/ —Â Cambrian
Altos Labs’ $3 Billion Launch to Reverse Cellular Aging
January 20, 2022
In September 2021, we reported that Altos Labs was about to launch an ambitious project to develop partial cellular reprogramming to the point where it could be safely used in humans to reverse cellular aging. That launch has now officially started, and Altos Labs is shaping